DaVita Cost of Goods Sold 2010-2024 | DVA
DaVita annual/quarterly cost of goods sold history and growth rate from 2010 to 2024. Cost of goods sold can be defined as the difference between beginning and ending inventories for tangible products resulting in an expense that reflects production and sales costs.
- DaVita cost of goods sold for the quarter ending September 30, 2024 was $2.152B, a 4.09% increase year-over-year.
- DaVita cost of goods sold for the twelve months ending September 30, 2024 was $8.512B, a 2.92% increase year-over-year.
- DaVita annual cost of goods sold for 2023 was $8.32B, a 1.34% increase from 2022.
- DaVita annual cost of goods sold for 2022 was $8.21B, a 2.97% increase from 2021.
- DaVita annual cost of goods sold for 2021 was $7.972B, a 0.2% decline from 2020.
DaVita Annual Cost of Goods Sold
(Millions of US $) |
| 2023 |
$8,320 |
| 2022 |
$8,210 |
| 2021 |
$7,972 |
| 2020 |
$7,989 |
| 2019 |
$7,914 |
| 2018 |
$8,196 |
| 2017 |
$7,640 |
| 2016 |
$7,432 |
| 2015 |
$6,856 |
| 2014 |
$9,119 |
| 2013 |
$8,198 |
| 2012 |
$5,584 |
| 2011 |
$4,634 |
| 2010 |
$4,428 |
| 2009 |
$4,242 |
DaVita Quarterly Cost of Goods Sold
(Millions of US $) |
| 2024-09-30 |
$2,152 |
| 2024-06-30 |
$2,142 |
| 2024-03-31 |
$2,079 |
| 2023-12-31 |
$2,138 |
| 2023-09-30 |
$2,067 |
| 2023-06-30 |
$2,056 |
| 2023-03-31 |
$2,058 |
| 2022-12-31 |
$2,089 |
| 2022-09-30 |
$2,086 |
| 2022-06-30 |
$2,017 |
| 2022-03-31 |
$2,019 |
| 2021-12-31 |
$2,060 |
| 2021-09-30 |
$2,009 |
| 2021-06-30 |
$1,965 |
| 2021-03-31 |
$1,938 |
| 2020-12-31 |
$2,057 |
| 2020-09-30 |
$1,972 |
| 2020-06-30 |
$1,985 |
| 2020-03-31 |
$1,975 |
| 2019-12-31 |
$2,001 |
| 2019-09-30 |
$1,991 |
| 2019-06-30 |
$1,958 |
| 2019-03-31 |
$1,965 |
| 2018-12-31 |
$2,027 |
| 2018-09-30 |
$2,064 |
| 2018-06-30 |
$2,069 |
| 2018-03-31 |
$2,036 |
| 2017-12-31 |
$1,942 |
| 2017-09-30 |
$1,952 |
| 2017-06-30 |
$1,895 |
| 2017-03-31 |
$1,852 |
| 2016-12-31 |
$-519 |
| 2016-09-30 |
$2,698 |
| 2016-06-30 |
$2,671 |
| 2016-03-31 |
$2,582 |
| 2015-12-31 |
$-454 |
| 2015-09-30 |
$2,501 |
| 2015-06-30 |
$2,446 |
| 2015-03-31 |
$2,363 |
| 2014-12-31 |
$2,366 |
| 2014-09-30 |
$2,327 |
| 2014-06-30 |
$2,247 |
| 2014-03-31 |
$2,180 |
| 2013-12-31 |
$2,128 |
| 2013-09-30 |
$2,095 |
| 2013-06-30 |
$2,014 |
| 2013-03-31 |
$1,961 |
| 2012-12-31 |
$1,707 |
| 2012-09-30 |
$1,327 |
| 2012-06-30 |
$1,299 |
| 2012-03-31 |
$1,249 |
| 2011-12-31 |
$1,167 |
| 2011-09-30 |
$1,190 |
| 2011-06-30 |
$1,163 |
| 2011-03-31 |
$1,114 |
| 2010-12-31 |
$1,090 |
| 2010-09-30 |
$1,144 |
| 2010-06-30 |
$1,111 |
| 2010-03-31 |
$1,083 |
| 2009-12-31 |
$1,089 |
| 2009-09-30 |
$1,096 |
| 2009-06-30 |
$1,052 |
| 2009-03-31 |
$1,006 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$12.872B |
$12.140B |
|
DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end-stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services. DaVita's Dialysis and related lab services business segment provides inpatient as well as outpatient dialysis services, routine laboratory testing for ESRD patients and management services to outpatient dialysis centers. The company's other ancillary services and strategic initiatives segment includes its international dialysis services, pharmacy services, infusion therapy services, disease management services, vascular access services, ESRD clinical research programs and physician services.
|
